Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2015 (Event Date: November 20, 2015)
Context: The Company entered into a Material Definitive Agreement to conduct a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Size: 4,761,900 shares of Common Stock.
- Purchase Price: $2.06 per share.
- Gross Proceeds: $9,809,514 (before fees and expenses).
- Warrant Terms: Purchasers receive warrants to purchase 0.75 shares for every share purchased (totaling 3,571,425 warrant shares).
- Warrant Exercise Price: $2.50 per share.
- Warrant Exercise Period: Begins 6 months after issuance; expires 5 years after the initial exercise date.
- Placement Agent Fee: 6.0% of gross proceeds plus reimbursement of out-of-pocket expenses.
- Placement Agent: Roth Capital Partners, LLC.
Material Changes and Restrictions
The filing discloses a significant capital raise event. As part of the Purchase Agreement, the Company agreed to a lock-up provision restricting future stock issuances:
- Issuance Restriction: For 120 days following the closing, the Company cannot issue (or agree to issue) any Common Stock or Common Stock equivalents, subject to specific exceptions.
- Registration Rights: The Company must file a Form S-3 registration statement within 30 calendar days of closing to allow for the resale of Warrant Shares.
Outlook, Risks, and Unusual Items
Management Commentary: The offering is being conducted pursuant to an effective shelf registration statement (File No. 333-194747) originally filed in March 2014. The Warrants are being offered in a concurrent private placement under Section 4(a)(2) of the Securities Act and are not registered under the Securities Act of 1933.
Risks and Contingencies:
- Dilution: The issuance of 4,761,900 shares plus potential exercise of 3,571,425 warrants represents significant potential dilution to existing shareholders.
- Market Conditions: The offering is on a "reasonable best efforts" basis, implying no guarantee of full subscription.
- Resale Restrictions: Warrants and Warrant Shares cannot be resold to the public unless registered or exempted under the Securities Act.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting the 6% placement fee and other offering expenses.
- Confirm the filing of the required Form S-3 registration statement for Warrant Shares within the 30-day window.
- Review the definitive Purchase Agreement (Exhibit 10.1) for specific exceptions to the 120-day issuance lock-up.
- Assess the impact of the 0.75 warrant ratio on future share count and potential dilution at the $2.50 exercise price.
- Check the press release (Exhibit 99.1) for management's stated use of proceeds.